As EGFR has been identified as a promising target for cancer patients for some time, several potent drugs, (e.g. Gefitinib, Erlotinib, Cetuximab, Lapatinib etc.), all approved for the treatment of cancer patients, have been tested in clinical breast cancer studies with overall disappointing results [4]. This evidence concerns the gene EGFR and breast carcinoma.